Contineum Therapeutics (CTNM) Invested Capital (2023 - 2025)
Historic Invested Capital for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $180.5 million.
- Contineum Therapeutics' Invested Capital fell 1415.51% to $180.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.5 million, marking a year-over-year decrease of 1415.51%. This contributed to the annual value of $198.1 million for FY2024, which is 39154.79% up from last year.
- Latest data reveals that Contineum Therapeutics reported Invested Capital of $180.5 million as of Q3 2025, which was down 1415.51% from $171.4 million recorded in Q2 2025.
- In the past 5 years, Contineum Therapeutics' Invested Capital ranged from a high of $217.5 million in Q2 2024 and a low of -$75.6 million during Q1 2024
- In the last 3 years, Contineum Therapeutics' Invested Capital had a median value of $182.6 million in 2025 and averaged $127.4 million.
- Per our database at Business Quant, Contineum Therapeutics' Invested Capital skyrocketed by 39154.79% in 2024 and then crashed by 2120.11% in 2025.
- Quarter analysis of 3 years shows Contineum Therapeutics' Invested Capital stood at -$67.9 million in 2023, then surged by 391.55% to $198.1 million in 2024, then decreased by 8.88% to $180.5 million in 2025.
- Its Invested Capital was $180.5 million in Q3 2025, compared to $171.4 million in Q2 2025 and $184.8 million in Q1 2025.